Title |
Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease
|
---|---|
Published in |
European Archives of Psychiatry and Clinical Neuroscience, June 2017
|
DOI | 10.1007/s00406-017-0815-9 |
Pubmed ID | |
Authors |
Panagiotis Alexopoulos, Lena-Sophie Gleixner, Lukas Werle, Felix Buhl, Nathalie Thierjung, Evangelia Giourou, Simone M. Kagerbauer, Philippos Gourzis, Hubert Kübler, Timo Grimmer, Igor Yakushev, Jan Martin, Alexander Kurz, Robert Perneczky |
Abstract |
The established biomarkers of Alzheimer's disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein β (sAPPβ), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPPβ in plasma as an AD biomarker candidate. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 35 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 5 | 14% |
Other | 4 | 11% |
Researcher | 3 | 9% |
Professor | 2 | 6% |
Student > Master | 2 | 6% |
Other | 6 | 17% |
Unknown | 13 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 17% |
Neuroscience | 4 | 11% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Agricultural and Biological Sciences | 2 | 6% |
Psychology | 2 | 6% |
Other | 6 | 17% |
Unknown | 12 | 34% |